REG - Proteome Sciences - Appointment of Chief Financial Officer

Proteome SciencesAnnouncement

18/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220818:nRSR3695Wa&default-theme=true

RNS Number : 3695W  Proteome Sciences PLC  18 August 2022

 
 

 

18 August 2022

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Appointment of Chief Financial Officer

 

The Board of Proteome Sciences plc is pleased to announce that Abdelghani
Omari has been appointed as the Company's new Chief Financial Officer. He will
take up the position on September 1st, 2022 and will become a director of the
Company.

 

Abdel joins Proteome Sciences from Paion AG, a listed speciality
pharmaceutical company, where he has been CFO and since 2014 a member of the
management board.  During his time at Paion he has negotiated numerous
license agreements with pharma companies and has raised more than 150 million
Euros in financing from investors in the U.S. and in Europe. In addition to
the finance role, Abdel was also responsible for HR, IT, Legal, IP &
Compliance and more recently investor relations.  Abdel has more than 20
years' experience in finance, starting his career at KPMG Audit after a
business degree from the University of Aachen.  At KPMG he worked in audit
and financial consultancy roles prior to joining Paion.

 

Proteome Sciences' Chief Executive Officer, Dr Mariola Soehngen, commented
"The Board and the Company welcome Abdel as Proteome Sciences' CFO at this
important point in the company's growth. Abdel brings a wealth of relevant
experience to the team as we pursue the Company´s strategy of organic growth,
to grow the business through adding new high value services to our portfolio
and enter into further internationalisation of the business.

 

Commenting on his appointment, Abdel said "I am very excited to join Proteome
Sciences at this stage. The Company has a unique technology and highly skilled
and committed people. Proteome Sciences has an exciting journey ahead and I am
pleased to be joining the Company as we shape and accelerate its future
growth."

 

As part of Mr Omari's remuneration package, three months after his appointment
he will be granted 4,000,000 options under the Company's share option scheme
("Options"). The Options will be exercisable at the market price on the day of
award per Option and will vest in three equal annual tranches on 1 September
2023, 1 September 2024 and 1 September 2025. Each Option is exercisable into
one Ordinary Share and once vested, can be exercised up until the 10th
anniversary.

 

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Mr Abdelghani Omari
(aged 45) has held the following directorships or partnerships in the past
five years:

 Current                     Previous
 Paion AG, Germany, Pharma   Paion Inc, USA

 Paion Holdings UK Ltd, UK   Paion Scandic, Aps, Denmark

 Paion UK Ltd, UK

 TheraSci Ltd, UK

 Paion Netherlands B.V.

 

There is no further information on Abdelghani Omari required to be disclosed
under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

 

For further information:

 Proteome Sciences plc
 Proteome Sciences plc
 Dr Mariola Soehngen, Chief Executive Officer         Tel: +44 (0)20 7043 2116
 Dr Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer
 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter (Corporate Finance)  Tel: +44 (0) 20 3328 5656

 Tony Quirke (Sales)

 

 

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant(®) and TMT(®)MS2 are unbiased methods for
identifying and contextualising new targets and defining mechanisms of
biological activity, while analysis using Super-Depletion and TMTcalibrator™
provides access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in Cobham, UK, with laboratory facilities in
Frankfurt, Germany.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZDLFFLVLBBBE